EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/111385
February 2013 In the journal ��� February 2013 EW NEWS & OPINION 11 Harvard medical school faculty members to deliver 2013 ASCRS Science and Medicine Lecture by Cindy Sebrell ASCRS���ASOA Director of Public Affairs Loteprednol etabonate ophthalmic suspension Stephen S. Lane, M.D., Edward J. Holland, M.D. In routine cataract patients, is it preferable to use 0.5% loteprednol etabonate or 1% prednisolone acetate for the control of post-op inflammation? In this comparative case series of 88 patients, investigators set out to determine this. After cataract removal, in which everyone was given 0.09% bromfenac and 0.6% besifloxacin, patients were randomly assigned to receive either loteprednol etabonate or prednisolone acetate. Investigators determined that particularly on the one- and three-day marks there was more fluctuation in IOP in those treated with prednisolone acetate than with loteprednol etabonate. However, when it came to controlling inflammation, the two treatment groups proved equivalent. Investigators concluded that both drugs could provide equivalent inflammation control, but that there are fewer IOP fluctuations with loteprednol etabonate. Biometry in highly myopic eyes Peiyang Shen, M.D., Yingfeng Zheng, M.D., Xiaohu Ding, M.D., Bin Liu, M.D., Nathan Congdon, M.D., Ian Morgan, Ph.D., Mingguang He, M.D. In this evaluation, the aim was to compare how different methods of optical biometry fared in highly myopic eyes of ���6 D or more. Investigators assessed the accuracy and repeatability of optical biometry in these high myopes using optical low-coherence reflectometry (OLCR), IOLMaster (Carl Zeiss Meditec, Jena, Germany) partial coherence interferometry, and applanation ultrasound biometry. They determined that for repeated axial length measurements using optical low-coherence reflectometry measurements were 0.06%, with IOLMaster partial coherence interferometry (PCI) this was 0.07%, and using applanation ultrasound this was 0.20%. Investigators found that the limits of agreement for axial length with OLCR and PCI were 0.11 mm, compared with 1.01 mm for OLCR and applanation ultrasound and 1.03 mm for PCI and ultrasound. They also determined that the mean anterior chamber depth values were 0.29 mm with OLCR, 0.53 mm with PCI, and 0.51 mm with applanation ultrasound biometry. The conclusion reached here was that in highly myopic eyes, biometric measurements were more repeatable and precise when measures of axial length and anterior chamber depth were used than with applanation ultrasound biometry. Review/update: Multifocal IOL in cataract surgery Niels E. de Vries, M.D., Rudy M.M.A. Nuijts, M.D. The aim of this review of the literature was to determine where in the current cataract surgery realm multifocal intraocular lenses stood. Investigators reviewed how patients��� near and distance acuity fared with implantation of diffractive, refractive, and hybrid diffractive-refractive multifocal designs and considered how spectacle independence was affected by these lenses. They also honed in on the potential visual affects sometimes found with multifocal IOLs, such as the occurrence of photic phenomena and loss of contrast sensitivity. Pamela Hartzband, M.D., and Jerome Groopman, M.D. T wo well-known authors and members of the Harvard Medical School faculty will co-deliver the annual Science and Medicine Lecture at the ASCRS���ASOA Symposium & Congress this April in San Francisco. Jerome Groopman, M.D., and Pamela Hartzband, M.D., will deliver the lecture, titled ���When Experts Disagree: A New Approach to Medical Decision Making,��� at 10 a.m. on Sunday, April 21, during the Opening General Session. Dr. Groopman holds the Dina and Raphael Recanati Chair of Medicine at Harvard Medical School and is chief of experimental medicine, Beth Israel Deaconess Medical Center, Boston. Dr. Groopman has authored numerous editorials on policy issues in the New York Times, the Wall Street Journal, The New Republic, and the Washington Post. He is currently a staff writer in medicine and biology for The New Yorker. His first popular book, The Measure of Our Days (1997), explores the spiritual lives of patients with serious illness and served as the basis for the ABC Television series ���Gideon���s Crossing.��� His other books include Second Opinions (2000), The Anatomy of Hope (2004), and How Doctors Think (2007), two of which were New York Times bestsellers. Dr. Groopman and Dr. Hartzband are co-authors of Your Medical Mind, a 2011 release that explains how patients can cut through the myriad of information from doctors, drug companies, and friends to arrive at positive medical decisions. They also co-author a bimonthly column for ACP Internist, the publication of the American College of Physicians, which is read by 150,000 internal medicine physicians in the U.S. and Canada. Dr. Groopman���s research has focused on blood development, cancer, and AIDS. Currently, his basic laboratory research involves understanding how blood and vascular continued on page 12